Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jennifer S Michaelson

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
Cytokine|February 24, 2009
TNF-like weak inducer of apoptosis (TWEAK) induces inflammatory and proliferative effects in human kidney cellsHua-Xin Gao, Sean R Campbell, Linda C Burkly, et al.
The Journal of Investigative Dermatology|April 1, 2015
TWEAK/Fn14 Signaling Involvement in the Pathogenesis of Cutaneous Disease in the MRL/lpr Model of Spontaneous LupusJessica L Doerner, Jing Wen, Yumin Xia, et al.
Arthritis Research & Therapy|September 30, 2009
Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort studyNoa Schwartz, Tamar Rubinstein, Linda C Burkly, et al.
The Journal of Clinical Investigation|August 20, 2005
TWEAK induces liver progenitor cell proliferationAniela Jakubowski, Christine Ambrose, Michael Parr, et al.
Mabs|June 24, 2011
Development of an Fn14 agonistic antibody as an anti-tumor agentJennifer S Michaelson, Aldo Amatucci, Rebecca Kelly, et al.
Mabs|January 12, 2010
Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaRJennifer S Michaelson, Stephen J Demarest, Brian Miller, et al.
Journal for Immunotherapy of Cancer|March 15, 2022
A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALLNaveen K Mehta, Martin Pfluegler, Kristan Meetze, et al.
Journal for Immunotherapy of Cancer|February 4, 2026
Dysregulated expression of the tumor suppressor p14ARF in cancer provides an effective target for TCR-T cell therapeuticsThomas M Schmitt, Kelsey Furiya, Cheryl Black, et al.
The EMBO Journal|November 25, 2006
TWEAK, via its receptor Fn14, is a novel regulator of mesenchymal progenitor cells and skeletal muscle regenerationMahasweta Girgenrath, Shawn Weng, Christine A Kostek, et al.
Cancer Research|October 5, 2006
Increased fibroblast growth factor-inducible 14 expression levels promote glioma cell invasion via Rac1 and nuclear factor-kappaB and correlate with poor patient outcomeNhan L Tran, Wendy S McDonough, Benjamin A Savitch, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Cytokine|February 24, 2009
TNF-like weak inducer of apoptosis (TWEAK) induces inflammatory and proliferative effects in human kidney cellsHua-Xin Gao, Sean R Campbell, Linda C Burkly, et al.
The Journal of Investigative Dermatology|April 1, 2015
TWEAK/Fn14 Signaling Involvement in the Pathogenesis of Cutaneous Disease in the MRL/lpr Model of Spontaneous LupusJessica L Doerner, Jing Wen, Yumin Xia, et al.
Arthritis Research & Therapy|September 30, 2009
Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort studyNoa Schwartz, Tamar Rubinstein, Linda C Burkly, et al.
The Journal of Clinical Investigation|August 20, 2005
TWEAK induces liver progenitor cell proliferationAniela Jakubowski, Christine Ambrose, Michael Parr, et al.
Mabs|June 24, 2011
Development of an Fn14 agonistic antibody as an anti-tumor agentJennifer S Michaelson, Aldo Amatucci, Rebecca Kelly, et al.
Mabs|January 12, 2010
Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaRJennifer S Michaelson, Stephen J Demarest, Brian Miller, et al.
Journal for Immunotherapy of Cancer|March 15, 2022
A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALLNaveen K Mehta, Martin Pfluegler, Kristan Meetze, et al.
Journal for Immunotherapy of Cancer|February 4, 2026
Dysregulated expression of the tumor suppressor p14ARF in cancer provides an effective target for TCR-T cell therapeuticsThomas M Schmitt, Kelsey Furiya, Cheryl Black, et al.
The EMBO Journal|November 25, 2006
TWEAK, via its receptor Fn14, is a novel regulator of mesenchymal progenitor cells and skeletal muscle regenerationMahasweta Girgenrath, Shawn Weng, Christine A Kostek, et al.
Cancer Research|October 5, 2006
Increased fibroblast growth factor-inducible 14 expression levels promote glioma cell invasion via Rac1 and nuclear factor-kappaB and correlate with poor patient outcomeNhan L Tran, Wendy S McDonough, Benjamin A Savitch, et al.
Pageof 5